Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of lorazepam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of lorazepam can be broken down into several components which progressively intensify proportional to dosage. The general head space of lorazepam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Lorazepam is described as extremely psychologically addictive with a very high dependence potential. Compulsive redosing is commonly reported, and the risk of abuse is increased in individuals with pre-existing substance dependence or psychiatric disorders.
Physical dependence develops rapidly, with withdrawal symptoms possible after as little as one week of therapeutic use. Discontinuation can be life-threatening without proper medical tapering, with serious risk of seizures, hypertension, and death. As a potent short-acting benzodiazepine, lorazepam carries the highest risk of dependence within its class.
Lorazepam has relatively low toxicity when taken alone, and fatal overdoses on benzodiazepines without other substances are rare and less common than with barbiturates. However, overdose can result in profound sedation, deep respiratory depression, coma, and death, particularly when combined with other CNS depressants such as alcohol or opioids.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 1850 mg/kg |
Long-term use may cause cognitive deficits, particularly affecting memory and new memory formation; these effects may persist for at least six months after discontinuation and may only be partially reversible, especially in elderly users.
Psychosis is rare during therapeutic or recreational use but can occur as a withdrawal symptom following abrupt discontinuation after chronic use. Paradoxical reactions including hallucinations and delirium occur in less than 1% of the general population but are more common in recreational abusers, individuals with psychiatric disorders, children, and those on high-dose regimens.
Lorazepam has anticonvulsant properties and suppresses seizures during active use. However, abrupt withdrawal after regular use poses a significant seizure risk that can be life-threatening. Paradoxical worsening of seizures may rarely occur, particularly in individuals with epilepsy. Gradual tapering under medical supervision is essential to prevent withdrawal seizures.
Lorazepam was initially patented in 1963 and is considered one of the "classical" benzodiazepines alongside diazepam, clonazepam, oxazepam, nitrazepam, flurazepam, bromazepam, and clorazepate. The compound was developed by D.J. Richards, who served as president of research at Wyeth Pharmaceuticals.…
UN Convention on Psychotropic Substances 1971 (Schedule IV)
Unconfirmed reports suggest lorazepam may be obtainable at some pharmacies without prescription in 0.5 mg and 1 mg formulations. Regulatory enforcement may vary.
Listed in Schedule IV of the Controlled Drugs and Substances Act alongside other benzodiazepines. Requires a valid prescription for lawful possession.
Controlled under Anlage III of the Betäubungsmittelgesetz (Narcotics Act) since August 1, 1986. Generally requires a narcotic prescription form, with an exception for preparations containing up to 2.5 mg lorazepam per dosage unit.
Controlled under the psychotropic substances act as a Group IV-P substance, designated as having low potential for abuse. Legal for medical, scientific, and manufacturing purposes with appropriate authorization.
Specifically named as a controlled substance under Verzeichnis B of Swiss narcotics legislation. Medicinal use is permitted with appropriate authorization.
Classified as a Class C drug under the Misuse of Drugs Act 1971. Listed under Schedule IV, Part I (CD Benz POM) of the Misuse of Drugs Regulations 2001, permitting possession with a valid prescription.
Legal for medical use under the Arzneimittelgesetz (AMG). Possession or sale without a prescription is prohibited under the Suchtmittelgesetz (SMG).
Regulated as a Class II psychotropic substance under national drug control laws. Prescriptions are generally limited to a seven-day supply.
Controlled as a Class C drug under the Misuse of Drugs Act 1975. Prescription required for lawful possession.
Classified as a Schedule III controlled substance since 2013. Requires prescription for lawful possession and use.
Requires a 'green prescription' (special controlled substance prescription). Possession or sale without valid prescription is prohibited.
Controlled under the Controlled Substances Act as a Schedule IV depressant. Possession without a valid prescription is illegal, as is sale without appropriate licensing.
10 sources cited
